Skip to main content
. 2021 May 12;22(4):555–566. doi: 10.1007/s40257-021-00610-x

Fig. 6.

Fig. 6

Mean (95% CI) platelet count over time after application of ruxolitinib cream in the phase III studies combined. BQL ruxolitinib cream treatment but PK samples below the quantification limit, Css steady-state concentration, Q1 to Q4 1st to 4th quartiles of ruxolitinib Css during VC period, PK pharmacokinetic, VC vehicle-controlled